Plain-English translation of NCT06846489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications— and —work well together to treat mantle cell lymphoma (a type of blood cancer) in people who have never been treated before. You would take as a daily pill while receiving infusions (through an IV) on a set schedule. The study wants to see how many people have their cancer completely go away after 12 months of treatment.
Mantle cell lymphoma is a serious blood cancer that is hard to treat, especially in older adults or those who cannot handle intensive chemotherapy. Researchers want to find out if this combination of medications offers a gentler but still effective treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
You would take (a pill) twice daily at home for up to 24 months, and receive infusions at the hospital—once a week during the first month, then once a month for the next 12 months, then once every 2 months. Throughout the study, you'll have regular blood tests and imaging scans to check how your cancer is responding. The main goal is to see if your cancer completely goes away within the first 12 months.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sun Yat-sen University
Enrollment target
~50 participants
Started
April 2025
Primary completion
February 2033
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qingqing Cai
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.